Literature DB >> 26926058

The utility of high-resolution intraoperative MRI in endoscopic transsphenoidal surgery for pituitary macroadenomas: early experience in the Advanced Multimodality Image Guided Operating suite.

Hasan A Zaidi1, Kenneth De Los Reyes1, Garni Barkhoudarian1, Zachary N Litvack1, Wenya Linda Bi1, Jordina Rincon-Torroella1, Srinivasan Mukundan2, Ian F Dunn1, Edward R Laws1.   

Abstract

OBJECTIVE: Endoscopic skull base surgery has become increasingly popular among the skull base surgery community, with improved illumination and angled visualization potentially improving tumor resection rates. Intraoperative MRI (iMRI) is used to detect residual disease during the course of the resection. This study is an investigation of the utility of 3-T iMRI in combination with transnasal endoscopy with regard to gross-total resection (GTR) of pituitary macroadenomas.
METHODS: The authors retrospectively reviewed all endoscopic transsphenoidal operations performed in the Advanced Multimodality Image Guided Operating (AMIGO) suite from November 2011 to December 2014. Inclusion criteria were patients harboring presumed pituitary macroadenomas with optic nerve or chiasmal compression and visual loss, operated on by a single surgeon.
RESULTS: Of the 27 patients who underwent transsphenoidal resection in the AMIGO suite, 20 patients met the inclusion criteria. The endoscope alone, without the use of iMRI, would have correctly predicted extent of resection in 13 (65%) of 20 cases. Gross-total resection was achieved in 12 patients (60%) prior to MRI. Intraoperative MRI helped convert 1 STR and 4 NTRs to GTRs, increasing the number of GTRs from 12 (60%) to 16 (80%).
CONCLUSIONS: Despite advances in visualization provided by the endoscope, the incidence of residual disease can potentially place the patient at risk for additional surgery. The authors found that iMRI can be useful in detecting unexpected residual tumor. The cost-effectiveness of this tool is yet to be determined.

Entities:  

Keywords:  ACTH = adrenocorticotropic hormone; AMIGO; AMIGO = Advanced Multimodality Image Guided Operating; FSGR = fat spoiled gradient echo; FSH = follicle-stimulating hormone; GH = growth hormone; GTR = gross-total resection; LH = luteinizing hormone; NTR = near-total resection; STR = subtotal resection; endoscope; iMRI = intraoperative MRI; intraoperative MRI; pituitary adenomas; resection

Mesh:

Year:  2016        PMID: 26926058      PMCID: PMC4992957          DOI: 10.3171/2016.1.FOCUS15515

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  30 in total

1.  Maximizing the extent of tumor resection during transsphenoidal surgery for pituitary macroadenomas: can endoscopy replace intraoperative magnetic resonance imaging?

Authors:  Philip V Theodosopoulos; James Leach; Robert G Kerr; Lee A Zimmer; Amanda M Denny; Bharat Guthikonda; Sebastien Froelich; John M Tew
Journal:  J Neurosurg       Date:  2010-04       Impact factor: 5.115

2.  Intraoperative MRI for transphenoidal procedures: short-term outcome for 100 consecutive cases.

Authors:  Todd W Vitaz; Kofi E Inkabi; Christopher J Carrubba
Journal:  Clin Neurol Neurosurg       Date:  2011-09-01       Impact factor: 1.876

3.  Transsphenoidal resection of sellar tumors using high-field intraoperative magnetic resonance imaging.

Authors:  Nicholas J Szerlip; Yi-Chen Zhang; Dimitris G Placantonakis; Marc Goldman; Kara B Colevas; David G Rubin; Eric J Kobylarz; Sasan Karimi; Monica Girotra; Viviane Tabar
Journal:  Skull Base       Date:  2011-07

4.  High-Field iMRI in transsphenoidal pituitary adenoma surgery with special respect to typical localization of residual tumor.

Authors:  Vincenzo Paterno'; Rudolf Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  2014-01-19       Impact factor: 2.216

5.  Transsphenoidal hypophysectomy.

Authors:  J Hardy
Journal:  J Neurosurg       Date:  1971-04       Impact factor: 5.115

6.  Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly.

Authors:  David Bellut; Martin Hlavica; Christoph Schmid; René L Bernays
Journal:  Neurosurg Focus       Date:  2010-10       Impact factor: 4.047

7.  One year experience with 3.0 T intraoperative MRI in pituitary surgery.

Authors:  David Netuka; Václav Masopust; Tomáš Belšán; Filip Kramář; Vladimír Beneš
Journal:  Acta Neurochir Suppl       Date:  2011

8.  The value of high-field MRI (3T) in the assessment of sellar lesions.

Authors:  K Pinker; A Ba-Ssalamah; S Wolfsberger; V Mlynarik; E Knosp; S Trattnig
Journal:  Eur J Radiol       Date:  2005-06       Impact factor: 3.528

9.  Intraoperative magnetic resonance imaging combined with neuronavigation: a new concept.

Authors:  C Nimsky; O Ganslandt; H Kober; M Buchfelder; R Fahlbusch
Journal:  Neurosurgery       Date:  2001-05       Impact factor: 4.654

10.  Feasibility of Polestar N20, an ultra-low-field intraoperative magnetic resonance imaging system in resection control of pituitary macroadenomas: lessons learned from the first 40 cases.

Authors:  Ruediger Gerlach; Richard du Mesnil de Rochemont; Thomas Gasser; Gerhard Marquardt; Juergen Reusch; Lioba Imoehl; Volker Seifert
Journal:  Neurosurgery       Date:  2008-08       Impact factor: 4.654

View more
  16 in total

Review 1.  iMRI During Transsphenoidal Surgery.

Authors:  Prashant Chittiboina
Journal:  Neurosurg Clin N Am       Date:  2017-08-18       Impact factor: 2.509

2.  The extended, transnasal, transsphenoidal approach for anterior skull base meningioma: considerations in patient selection.

Authors:  Joseph P Castlen; David J Cote; Hasan A Zaidi; Edward R Laws
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

3.  Endoscopic transsphenoidal surgery for biochemically and clinically non-functioning adenohypophyseal tumours in the elderly: experience from a single UK centre.

Authors:  Boon Leong Quah; Andrew Edwards-Bailey; Kanna Gnanalingham; Omar Pathmanaban; Hariclea Vasilopoulos; Federico Roncaroli; Tara Kearney; James Balogun; Konstantina Karabatsou
Journal:  Endocrine       Date:  2021-11-05       Impact factor: 3.633

Review 4.  Intraoperative MRI for Brain Tumors.

Authors:  Cara Marie Rogers; Pamela S Jones; Jeffrey S Weinberg
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 5.  Applications of Ultrasound in the Resection of Brain Tumors.

Authors:  Rahul Sastry; Wenya Linda Bi; Steve Pieper; Sarah Frisken; Tina Kapur; William Wells; Alexandra J Golby
Journal:  J Neuroimaging       Date:  2016-08-19       Impact factor: 2.486

6.  Improved Surgical Safety via Intraoperative Navigation for Transnasal Transsphenoidal Resection of Pituitary Adenomas.

Authors:  Rebecca L Achey; Michael Karsy; Mohammed A Azab; Jonathan Scoville; Bornali Kundu; Christian A Bowers; William T Couldwell
Journal:  J Neurol Surg B Skull Base       Date:  2019-01-21

7.  Intraoperative MRI in trans-sphenoidal surgery using frameless stereotaxis.

Authors:  Mitchell Stanton; Joyce Antony; Teresa Withers
Journal:  Surg Neurol Int       Date:  2021-04-19

Review 8.  Impact of intraoperative magnetic resonance imaging on gross total resection, extent of resection, and residual tumor volume in pituitary surgery: systematic review and meta-analysis.

Authors:  Victor E Staartjes; Alex Togni-Pogliorini; Vittorio Stumpo; Carlo Serra; Luca Regli
Journal:  Pituitary       Date:  2021-05-04       Impact factor: 4.107

Review 9.  Current Limitations of Intraoperative Ultrasound in Brain Tumor Surgery.

Authors:  Andrej Šteňo; Ján Buvala; Veronika Babková; Adrián Kiss; David Toma; Alexander Lysak
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

10.  Impact of Intraoperative 3-Tesla MRI on Endonasal Endoscopic Pituitary Adenoma Resection and a Proposed New Scoring System for Predicting the Utility of Intraoperative MRI.

Authors:  Masahiro Tanji; Hiroharu Kataoka; Masahiro Kikuchi; Tatsunori Sakamoto; Fumihiko Kuwata; Mami Matsunaga; Takayuki Nakagawa; Yohei Mineharu; Yoshiki Arakawa; Kazumichi Yoshida; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-10-21       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.